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Background. Chronic medical conditions often occur in combination. Understanding underlying mechanisms causing diseases
and their interactions may make it possible to address multiple complex conditions with single or consolidated treatment
approaches and improve patients’ health outcomes while reducing costs. Objectives. We present a synthesis of the current
interprofessional discourse on the issues surrounding comorbidities. Methods. A targeted review of the literature was conducted
using published editorials, commentaries, and review articles. Results. Errors in conceptualization and measurement plague
our current understanding of comorbidities. Two potential paths to generating knowledge involve the use of etiological or
epidemiological approach. An etiological approach investigates the risk factors and underlying mechanisms potentially leading to
consolidation of diagnosis and treatments. Because of the rudimentary stage of knowledge development in this area, this approach
will require time and significant research investments. In contrast, the epidemiological approach relies on statistical identification
of disease entities that cooccur beyond random chance; this approach carries an accompanying risk of diagnostic and treatment
proliferation.Discussion. The concept of comorbidity, its nature, and measurement is in need of meaningful debate by the scientific
and clinical communities. Recommendations in the domains of conceptualization, research, and measurement are discussed.
1. Introduction
Chronic medical conditions rarely occur in isolation but
rather in combination, as comorbidities. Successful man-
agement of chronic conditions is associated with complex
treatment regimens and requires adequate self-care by the
patient of all comorbid conditions. Improving self-care
among patients with chronic illness therefore necessitates a
better understanding of the complexities of comorbidity.
While the concept of comorbidity was introduced in
medicine almost four decades ago [1], its scientific underpin-
nings remain underdeveloped with consequent uncritical use
and application of this concept in research and practice [2, 3].
The difficult issue of comorbidities has been appropriately
referred to in the literature as a “puzzle,” “tapestry” [4],
“Gordian Knot” [5], and something that embodies “dizzying”
levels of complexity [6]. Thus the concept of comorbidity
remains in continued need of discourse and development.
Recently, both research and clinical communities have begun
to pay close attention to the complexity of comorbidities in
an attempt to appreciate its scope and utility for enhancing
practice and patient outcomes [7–9]. Specific calls have been
made for changes for the multimorbid in (1) how quality
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is measured, (2) how health care is delivered and paid
for, and (3) informed clinical decision making [10, 11]. But
comorbidity continues to be plagued by two critical errors
rooted in the conceptualization and measurement of the
concept. Because of these errors, any current definition of
comorbidity should be endorsed carefully. Furthermore, the
science cannot advance until they are addressed.
To better understand and delineate these conceptualiza-
tion and measurement issues, an integrative review of the
current interprofessional discourse surrounding comorbidity
was conducted using published editorials, commentaries, and
review articles. A literature search was carried out using ISI
Web of Science (Science Citation Index Expanded and Social
Sciences Citation Index). Review and editorial materials
published in the English language between 1999 and 2012
were searched using the terms “comorbid,” “comorbidity,” and
“comorbidities” in the title, resulting in 1,354 titles. Meeting
abstracts (𝑛 = 526) and proceeding papers (𝑛 = 47) were
excluded, yielding 781 articles. Pediatric (𝑛 = 44) and empiric,
disease-specific articles were excluded, yielding a final set
of 29 articles. This resulted in a synthesis of the current
conceptual andmeasurement issues surrounding comorbidi-
ties and an offering of recommendations with potential to
address these issues. Future directions were identified in the
conceptual, measurement, and analytical domains.
2. Errors of Conceptualization
Correct conceptualization of comorbidity is a necessary
precondition for knowledge development. The correct ascer-
tainment of comorbidity inevitably depends upon the cor-
rect identification of the underlying etiology. The etiolog-
ical science is constantly evolving and will always remain
imperfect. In the absence of sound etiological grounding,
the science of comorbidity has been criticized for being
atheoretical or without a theoretical base [12, 13]. Four prob-
lems currently confound the advancement of comorbidity
conceptualization—the presence of heterogeneous defini-
tions, an inadequate nosological system, a lack of modeling
of the dynamic patterns of relationships between chronic
conditions, and an atheoretical understanding of the causes
and predictors of comorbidity.
2.1. Problem Number 1—Heterogeneous Definitions. The term
comorbidity was introduced by Feinstein in 1970 to sig-
nify a “distinct additional clinical entity” occurring in the
setting of an index disease [1]. The term has been used
loosely in the literature to imply either “coexisting” diseases
or “cooccurring” diseases (Figure 1). Although often used
interchangeably, important distinctions exist; for instance,
the simultaneous presence of multiple health conditions is
also termed “coexisting diseases,” “multiple pathology,” and
“multimorbidity” when no single condition can be identified
as an index disease [4, 14]. On the other hand, comorbidities
are termed “cooccurring diseases,” “concomitant diseases,”
and “disease clustering” when diseases cooccur at a sig-
nificantly higher rate than expected by chance alone [14].
Thus, the existing terms used to denote comorbidities have
Distinct disease 
entities 
Multimorbidity 
Concurrent 
Disease clustering 
Concomitant 
No co-dependence Co-dependence
Multiple pathology
Co-morbidity
Co-occurringCo-existing
≥2 or more diseases≥2 or more diseases
Figure 1: Multimorbidity versus comorbidity (illustration of con-
ceptual problem no. 1).
distinct conceptualizations and scientific implications while
still being used interchangeably.
2.2. Problem Number 2—Inadequate Nosological System. The
bulk of debate on the nature of comorbidities lies in the
domain of nosology or disease classification. This discourse
centers on the teasing part of real or true comorbidities
from artifacts or spurious comorbidities. To qualify as a
comorbid condition, Feinstein argued that each disease must
represent a “distinct” disease/clinical entity with unique
pathophysiology, course, and response to treatment while
sharing a common diathesis/etiology [15]. This is where
the conceptualization of comorbidity gets murky, as limited
nosological systems challenge the very foundation of the
comorbidity designation.
Thedesignation of a valid clinical entity (or taxon disease)
assumes that the diagnostic nosology is a concrete science,
which is far from the case. There have been several iterations
of both the Diagnostic and Statistical Manual of Mental
Disorders (DSM) and International Statistical Classification
of Diseases (ICD) with earlier versions differing significantly
from current ones. This is epitomized in the recognition
of depression and mania as “two distinct” clinical entities
until late 19th century to a “single” disease, bipolar disorder,
in the DSM-III (see Figure 2). Further, the “operational
rules” used in the construction of the DSM creates a clin-
ical scenario of diagnostic proliferation when diseases may
actually be an extension of the same underlying process
[10, 12, 13]. For instance, anxiety is frequently present in
individuals with depression; however, the rule in the DSM
does not allow occurrence of the same symptom in more
than one disorder, resulting in the creation of additional DSM
diagnostic categories such as “mixed depressive-anxiety” [12,
13]. Thus, concomitance of two or more diagnoses may
indicate either the presence of distinct clinical entities or
point to multiple manifestations of a single clinical entity
[12, 13, 16, 17]. Contrary to the DSM, the ICD classification
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Figure 2: The relation between nosology, chronology and evolving science (illustration of conceptual problem no. 2).
allows for similar symptoms or indicator patterns to appear
in more than one disorder. Diseases with different etiologies
that produce similar pathology and symptoms are defined as
two separate diseases in the ICD classification. However, the
knowledge of diseases with shared etiologies, but disparate
clinical symptoms, is limited. Further, physical and psycho-
logical conditions remain in silos based on an oversimplified
approach to studying diseases that dichotomize themind and
body [12, 13, 17]. The 22 chapters of the ICD-10 are organized
according to organ systems, and one chapter is devoted to
mental and behavioral disorders [18]. Thus, the nosologies
are destined to remain arbitrary within the limitations of the
existing science and are based on operational rather than
theory-based diagnostic criteria [6, 10, 12, 13].
Consequently, some authors have advocated for an epi-
demiological approach to identifying common patterns of
cooccurrence that will offer directions for further rigorous
investigation of etiology [19]. The idea is to employ an a
fortiori approach using observed morbidities and estimate if
these conditions cooccur beyond random chance or expected
rates of overlap [11, 19]. Other authors warn that a fortiori
categorization or use of observational variables to arrive at
taxon disease entities is unlikely to be useful or may even be
harmful [2] and advocate for a more direct investigation of
etiological factors that can distinguish taxon disease entities
from regions of artifact [2]. Specifically, Drake warns that
too much reliance on manifest symptoms can lead to “con-
fused and confusing attempts” to classify and treat diseases
[20] resulting in diagnostic proliferation and unnecessary
polypharmacy.
2.3. Problem Number 3—Dynamic Patterns of Relationships.
As noted earlier, the simultaneous presence of multiple
health conditions is termed as comorbidity when there is
an index condition as well as other distinct conditions and
as multimorbidity when no single condition is identified
as an index disease [4, 14]. An index disease refers to a
condition or core mechanisms with relatively large impact
on the development of comorbidity, its course and outcomes
[21]. While operationally appropriate, the above conceptual-
izations undermine the dynamic and heterogeneous nature of
comorbidities.
C. van Weel and Schellevis [22] proposed four categories
to capture the complex relationships among disease entities:
(1) causal (diseases with a common pathophysiology), (2)
complicating (disease-specific complicating morbidity), (3)
concurrent (coexisting chronicmorbiditywithout any known
causal relation to the index disease), and (4) intercurrent
(referring to interacting acute illness, usually limited in time).
Based on evidence, additional levels of complexities can be
introduced in the above categorization (see Figure 3). The
antecedent-consequent (Figure 3(B)) category may be further
confounded by the evidence of reciprocal (Figure 3(C))
and bidirectional association between diseases [23, 24]. For
instance, heart disease and diabetes may increase risk for
depression and depression may in turn increase the risk for
cardiovascular disease and diabetes [19, 21]. Further, several
antidepressants have anti-inflammatory properties and anti-
inflammatory agents such that cyclooxygenase-2-selective
inhibitors have been found to offer mood stabilizing benefits
[21] suggesting presence of a principal or causal (Figure 3(D))
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Figure 3: Dynamicity: patterns of relationships and complexities (illustration of conceptual problem no. 3).
underlying mechanism responsible for multiple clinical con-
ditions. Similarly, complicating morbidity, as proposed by
van Weel and Schellevis, assumes an antecedent temporal
relationship of an index disease to a consequent disease
which may be arbitrary. This is because a latent-manifest
(Figure 3(E)) relation among diseases is plausible; often
clinical diagnoses are based on manifest indicators whereas
an assumed consequent disease may have been present for
years below the threshold level for clinical diagnosis [2].
Further, the relationship among diseases is complicated by
other variables often neglected in comorbidity conceptual-
ization and measurement such as stage, severity, complexity
[6], health status, frailty, disability [25], and differences
across socioeconomic, racial, gender, and age groups [8].
The specific interactions among risk factors and diseases
may have synergistic, additive, or multiplicative effects on
outcomes [14, 19].
Adding further levels of complexity in the understanding
of patterns of relationships between diseases is the classifi-
cation of diseases as distinct entities when in fact they may
share underlying genetic homogeneity. Our human genome
(the composite total of all of our chromosomes) is 99.9%
identical within each individual; however, the genome is so
large that there are about 3millionways inwhichwe can differ
from one another [26]. Some of these differences predispose
individuals to disease susceptibility. This is compounded by
epigenetic factors, or our risk exposures in life, in which
genetic expression can be altered [27, 28]. In effect, the impact
of these genetic alterations can lead to health aberrations that
manifest throughout multiple body systems, thus contribut-
ing to underlying comorbid pathophysiological processes.
2.4. Problem Noumber 4—Atheoretical Understanding of
Causes and Predictors. An understanding of the causes
encompassing both the mechanisms and explanations of
those mechanisms and predictors of unique patterns of
comorbidities is the least developed area in the comorbidity
literature. In an empirical review of causes and consequences
of comorbidity, only 4 of 82 studies were concerned with the
predictors of comorbidity [14]. This finding was supported
by a more recent review of empiric comorbidity studies
which found a similar lack of measurement of predictors
of comorbidity [29]. Studies of social, environmental, and
lifestyle risk factors are particularly lacking in the literature
[14, 23, 30]. The paucity of research on antecedents versus
consequences is understandable since consequences are rela-
tivelymore straightforward to investigate andmore rewarded
in the prevailing culture of outcome-based medicine. In
contrast, understanding etiologies represents a nearly insur-
mountable task of understanding a complex interplay of
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genetic, epigenetic, biological, neurochemical, structural,
social, environmental, and situational risk factors with other
intervening mediating and moderating variables [2, 4, 12, 16,
23]. Nevertheless, the predictor-based approach to under-
standing comorbidities is important since the risk factors for
comorbidities are not randomly distributed in the population
[4].
Further, there is a lack of critical use of certain variables
as predictors of comorbidities. The variable of age is a
case in point. Epidemiological and registry data for various
incident diseases suggest that a number of comorbidities
increase with age [4, 14, 31, 32]. It has been suggested that
aging is related to increased burden of comorbidity and that
comorbidity will only increase in the face of increasing life
expectancy [4, 9]. Others have taken amore critical approach
to understanding the effect of age and have argued that
the disproportionate representation of certain age groups
may result in conflicting conclusions on the relationships
between age and comorbidity outcomes. For instance, Firat
et al. [31] note that selection bias based on age in clinical
trials precludes an understanding of the influence of age
on comorbidity-related outcomes. Using an example from
Dajczman et al. (as cited in Firat et al.), illustrated that
patients 70 years or older are systematically excluded from
cancer clinical trials. Only 1 of 81 patients older than 70 years
of age was treated as part of an investigational protocol for
small-cell lung cancer despite the evidence that a number of
“fit elderly” can tolerate cancer treatment protocols. Nonethe-
less the protocol developed based on the age discrepancy is
often accepted as the standard of care for all age groups [31].
In contrast, a Radiation Therapy Oncology Group (RTOG)
study of concurrent chemotherapy and radiation therapy
among “fit elderly” patients demonstrated greater survival
benefits in older persons when compared to younger patients,
illustrating that age may not be categorically associated with
comorbidities and outcomes [31].
The quandary of age as an antecedent to comorbidity
and outcomes remains. Most authors have used an aging
society to underscore the significance of comorbidity work,
and others have explicitly described age as an independent
risk factor for comorbidities and multimorbidities [4, 6].
Stochastic risk factors that contribute to diseases increase
with age (e.g., environmental exposure to toxins, passive
smoking, and acquired genetic changes). Nevertheless, most
studies have investigated the “on-average” effect of age and the
risk may be different for subgroups of healthy-aged patients.
3. Errors in Measurement
Measurement influences everything currently known about
comorbidity. The presence of comorbidity causes two related
difficulties: one statistical and one clinical. The statistical
problem arises from a failure to classify and analyze patients
and their multiple diseases correctly resulting in misleading,
therapy-related, mortality data in populations and individ-
uals [1]. Clinically, comorbidity creates difficulties for both
patients and clinicians. For the patient, anticipated outcomes
from the index disease may differ based on the amount or
type of comorbidities present. For the clinician, diagnosis
becomes problematic as the index disease and comorbid dis-
easemay share signs and symptompatterns [33] complicating
the evaluation of treatments [1].
The statistical difficulties, however, have driven comor-
bidity measurement from the beginning [1] and continue
to exert an undue influence to today [3, 8, 34]. In clinical
research the focus has been on controlling for comorbidity
rather than understanding the particular condition and the
implications for the patient. In the mid-1970s, Kaplan and
Feinstein [33] grappled with taxonomic problems in classi-
fying diabetes as a disease entity. In the 1980s, Charlson and
colleagues [35] developed a comorbidity index to prospec-
tively identify patients at greater risk of death during clinical
trials. This focus on controlling for comorbidity continues
on into the digital age with the development of measures
utilizing ICD-10 codes [36–38] to aggregate large amounts
of administrative data to analyze mortality and resource uti-
lization patterns. For example, de Groot and colleagues [34],
in a widely cited critical review of comorbidity measurement
methods, listed four key reasons for careful measurement—
confounding, effect modification, prediction, and efficiency.
All four reasons are statistical rather than clinical and none
are patient centered. But despite this focus on statistical
precision there remain critical problems which result in
errors in the measurement of comorbidity, primarily related
to the presence of heterogeneous data sources, atheoretical
summary measures, and outcome selection bias.
3.1. Problem Number 1—Heterogeneous Data Sources. The
current identification of comorbidities is generally based on
multiple data sources (administrative data sources, medical
record review, clinician judgment, and patient interview)
[29], each with advantages and limitations [8]. For instance,
there are known limitations in using diagnostic data from
ICD-10 codes, Current Procedural Terminology (CPT) codes,
and discharge diagnoses as they pertain mainly to intensity
and currency of services used which may exclude chronic
diseases that are self-managed or pharmacologically man-
aged. Other challenges in using ICD codes include “up-
coding” (assigning a disease code associated with better
payment) [36], underreporting (including only the number
of secondary disease codes allowed by the database) [37], and
failing to distinguish comorbidities from complications of
care or severity indicators for the index disease [38]. Similarly,
the use of pharmacy databases to ascertain comorbidities
suffers from limitations, since participants may not have
uniform access to drugs or may fill their prescriptions at
pharmacies other than the one housing the database [8].
Using medical records as a data source requires the availabil-
ity of longitudinal data to assure accurate construction of a
comorbidity index. Even when available, the quality of data
may vary by setting (inpatient versus outpatient) [8], format
(electronic or paper-based), and quality of documentation
across providers. Further, certain populations such asminori-
ties, poor, uninsured/underinsured, elderly, and cognitively
impaired are at higher risk for poor quality of diagnosis and
documentation [4, 8]. Similarly, self-reported measures are
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limited due to risk of recall bias and may yield heterogeneous
data due to variability in patient reporting.
3.2. Problem Number 2—Atheoretical Summary Measures.
Regardless of the data source, the majority of comorbidity
measures are summary or aggregate measures. Although
summary measures are important in quantifying the effect of
an overall disease burden on outcomes, the greatest liability of
summarymeasures is that they do little to advance the science
underpinning comorbidities. Diseases occur on a continuum
from presence of risk factors, subclinical disease to clin-
ically detectable disease, progressing to multiple stages of
advancement. Some elements of this disease continuummay
not be amenable to direct observation or measurement. The
“dynamic” component of disease progression, including the
severity and rate of progress is beyondwhatmost comorbidity
instruments are able to capture. The operationalization of a
principal or index disease is often based on investigator’s lens
and serves the purpose of contextualization. Thus the major-
ity of the existing comorbidity measures are atheoretical
and consequently limited in their ability to prognosticate [9]
and advance science on diagnostic consolidation or common
treatment approaches.
Further, the existing measures and data sources may
have varying levels of sensitivity for specific outcomes. For
example in a study involving adults with lung cancer, comor-
bidity was related to survival outcomes when measured with
the Cumulative Index Rating Scale. However, no association
was found when the same outcome was measured using the
Charlson Comorbidity Index [31]. It is also important to
note that the most frequently used comorbidity measures
are generic and often measure “multimorbidity” or “coex-
isting diseases” rather than comorbidities. Such measures
may be appropriate for and sensitive to generic endpoints
but not necessarily useful for disease- or treatment-specific
outcomes.
3.3. Problem Number 3—Outcome Selection Bias. The out-
come of comorbidities can be classified as generic (e.g.,
functional status,mortality) or disease-specific. Similar to the
designation of an index disease, outcomes of comorbidities
depend directly upon how they are identified, operational-
ized, andmeasured in a given study. Unlike generic outcomes
that cut across diseases and comorbidities, disease-specific
outcomes typically necessitate specific operationalization and
tailored measurement. Disease- and treatment-specific out-
comes have been noted to affect course and progression of ill-
ness [19], tolerance and response to treatment and treatment-
related complications [19, 31], and behavioral outcomes [23].
It should be noted that outcomes in treatment-specific “effi-
cacy” trials are known to be influenced by patient selection
[31]. The presence of multimorbidity or certain types of
morbidities is frequently exclusion criteria in efficacy trials [4,
11], which in turn may affect the study of treatment response,
tolerance, and survival outcomes in the multimorbid.
A further example of potential selection bias was illus-
trated in the comprehensive review conducted by Gijsen
and colleagues [14] which concluded that while comorbidity
typically affected health outcomes across study designs,
settings, and outcomes with the effect remaining after adjust-
ment of relevant confounders; that mortality, functional
status, and quality of life were disproportionately reported
as consequences of comorbidity. Interestingly, psychiatric
comorbidities were found to be significantly associated with
poor functional status or quality of life, whereas physiologic
morbidities were associated with mortality. This may be arti-
fact as effects of psychiatric comorbidities on outcomes such
as mortality and health care utilization were seldom studied.
In the few studies that investigated mortality outcomes in
psychiatric comorbidities, mental disorders increased the
risk for mortality both from suicide and having a comorbid
disease [14]. The strong link of mental illness to worsening
of physical health, illness burden, and premature mortality
continues to be documented [19, 39].
From a health service perspective, comorbidities have
been found to be consistently related to healthcare utilization
and fiscal outcomes including cost, length of hospital stays,
and number of physician visits [4, 14, 29]. In addition,
there is evidence of interaction between age and patterns of
utilization [4, 14] such that higher numbers of comorbidities
in older adults are associated with more visits to both
specialists and primary care providers (PCPs). In contrast, in
the populations under 65 years, a greater number of specialist
visits than PCPs visits were observed across all morbidity
burden groups [4, 14].
4. Discussion
Despite accumulating literature, effective models for under-
standing, measuring, and addressing comorbidities are lack-
ing. The two major approaches in the literature to address
comorbidities are epidemiological and etiological (Figure 4).
The epidemiological approach requires identifying disease
entities that cooccur beyond random chance. This approach
is purported to be “atheoretical” with accompanying risk of
polypharmacy and diagnostic proliferation [4, 12, 13, 15, 40].
However, the etiological approach is in its rudimentary stages
of development possibly due to intractability of identifying
risk factors, shared mechanisms, interactions, and outcomes
around any combination of diseases. New conceptual models
are needed informed by an understanding of patterns of
relationships among clinical and subclinical disease entities
and mechanisms.
Further, current barriers to moving towards a theoretical
conceptualization of comorbidity need to be addressed.
For instance, while many studies have been conducted to
understand the consequences of comorbidities and multi-
morbidities, little research exists on common etiology and
combined risk factors [14]. Specifically lacking are studies
of psychological, environmental, and life-style risk factors
[11, 14]. Some authors have cautioned that the debate around
comorbidities should not be framed such that it leads to
overvaluing of physiologic and pharmacological theories
at the risk of undervaluing social etiologies [19, 20]. For
instance, conceptualizing comorbid mental illness and sub-
stance use disorder as merely physiological may undermine
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Figure 4: Closing the gap: translation of comorbidity science.
the sociohistorical etiology of this relationship brought about
by the closing and downsizing of mental health facilities [20].
Another barrier precluding research advancement relates
to operationalizing comorbidities based on historical disease
classification systems. Despite considerable evidence that
psychiatric diseases are frequently accompanied by physi-
cal morbidities [41], researchers studying comorbid mental
illnesses frequently fail to employ measures of physical
morbidity and vice versa.
Furthermore, failure to investigate comorbidities in
a manner that captures patient’s clinical complexity is
another factor precluding advancement of comorbidity sci-
ence. Investigators frequently exclude patients with complex
comorbidities from clinical trials and fail to identify, report,
and account for comorbidities in research even when they are
present [4]. These research limitations may help to explain
the clinical variability observed when protocols based on
disease-specific clinical trials are applied to people with com-
plex comorbidities [4]. Starfield [4] urged that rather than
excluding patients with complex morbidities, participants in
clinical trials should be characterized according to their total
morbidity burden including patterns and types of illnesses
followed by subgroup analysis to understand variability in
outcomes based on morbidity burden.
4.1. Recommendations for Addressing Conceptual and Meas-
urement Errors. Rigorous studies that capture the complexity
of comorbidities and its etiology from social, psychological,
and biological perspectives are needed (Table 1). Researchers
should carefully consider potential design and measurement
issues in designing studies. For instance, the ascertainment
of comorbidities depends upon both correctly applying
diagnostic algorithms and accurately recording diagnostic
data. This, in turn, depends upon factors including clinician’s
judgment, diagnostic skills, as well as accurate and complete
documentation in the medical records. Special attention
should be paid to inclusion of vulnerable populations such as
minorities, poor, uninsured/underinsured, elderly, and cog-
nitively impaired people who are disproportionately affected
by ascertainment bias [4, 8].
While correct ascertainment of comorbidities and min-
imizing sources of errors are important, these corrections
do not address the problems related to measurement. An
area in need of critical debate is the scientific approach to
addressing measurement gaps. The classical psychometric
approaches seek to identify consistency and homogeneity in
a phenomenon while “dehumanizing” clinical data to make
it amenable for statistical analysis [11, 42]. Psychometric
models alonemay not be appropriate for a heterogeneous and
dynamic concept like comorbidities.
5. Limitations
Certain limitations should be acknowledged in this paper.
This review was not meant to be systematic and exhaustive;
rather the purpose of this paper was to understand the
current fluid discourse and directions on comorbidities,
which research literature often misses due to focusing on
a narrow set of (often disease-specific) variables under
study. Thus nonempirical literature (reviews, editorials, and
commentaries) was deliberately selected to allow a more
inclusive understanding of this topic. Also, we limited our
literature search terms to the words “comorbid,” “comorbid-
ity,” and “comorbidities” in the title, which defined the pool
of included papers. Use of different search terms in different
databasesmay have resulted in the identification of additional
papers not included here. This should be kept in mind when
examining the findings. However, based on our experience
with an earlier systematic review conducted by members of
this group [29], we are confident that this search captured the
salient papers related to current interprofessional discourse
surrounding comorbidity.
6. Conclusions
Extant literature suggests that the nature of comorbidities is
defined by an evolving nosology, dynamic and heterogeneous
interactions between and among disease entities that may
not follow a clear antecedent-consequent relationship nor
linear-temporal progression. The index designation may be
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Table 1: Recommendations for improving comorbidity conceptualization and measurement.
Domain Directions
Conceptual
(i) Carve valid next steps with integrated input from clinicians, researchers, taxometricians, psychometricians, and
patients.
(ii) Develop complex conceptual models that capture the complexity of comorbidities while moving away from
mind-body, organ system dichotomies.
(iii) Conceptualize comorbidities in a manner that encourages investigation of both biological and social etiologies of
comorbidities and outcomes.
(iv) Keep the patient at the center of all conceptualization endeavors.
(v) Build the science from both epidemiological and etiological perspectives in tandem.
Research
(i) Design rigorous longitudinal comorbidity mapping projects that also collect comprehensive data on
sociodemographics, lifestyle factors, environmental factors, biomarkers, and outcomes.
(ii) Commit resources and funding (directed RFAs and supplements from major research agencies and across institutes).
(iii) Bridge gaps in understanding of physical and psychiatric morbidities.
(iv) Leverage epidemiological and statistical approaches to move comorbidity science from atheoretical to theoretical;
that is, model various sources of uncertainty (e.g., multiple bias modeling), amplify data through simulation (Monte
Carlo techniques), and improve understanding of relationships among variables (e.g., using Hybrid Structural Equation
modeling techniques combining observed and latent variable analysis).
(v) Interpret carefully findings within the limitations of an emerging science rather than as biological realities or
“scientific givens”.
(vi) Educate clinicians, researchers, and policymakers about the risks of atheoretical approaches to understanding
comorbidities including diagnostic proliferation, polypharmacy, and cost.
(vii) Include populations such as minorities, poor, uninsured/underinsured, elderly, cognitively impaired, and those
with complex morbidities who are disproportionately excluded from comorbidity research.
Measurement
(i) Characterize and minimize potential sources of erroneous inference.
(ii) Develop measures that capture complex and dynamic nature of comorbidities beyond numbers and severity of
diseases.
(iii) Incorporate a discussion on nontraditional measurement approaches such as clinimetrics in conceptualizing
measurement (e.g., approaching comorbidities using a battery of psychometric and clinimetric instruments that address
different dimensions of the phenomenon such as types, severity, trajectory of diseases or symptoms, and rates of
progression, clinical states such as functional capacity, and other aspects of health such as well-being and distress).
(iv) Develop measures that combine physical and psychological morbidities.
arbitrary in the absence of strong etiological science. The
consequences of comorbidity may be categorized as generic
(e.g., functional or fiscal) or disease-specific. Of particular
concern, the professional discourse is remarkably unchanged
from the early conceptual work [1] to today [11].
The goal of comorbidity science is to identify accurate
patterns of relationships between and among disease entities
and to reliably characterize their relationships to risk factors
and outcomes. Many questions remain in the conceptual and
measurement domains: What are the essential dimensions of
comorbidities? Is the current conceptualization in the context
of a distinct additional clinical entity serving as a red herring
distracting from the advancement of the conceptualization
of comorbidity? Should subclinical diseases, presence of
mechanisms (e.g., inflammation or oxidative stress), and
health states (e.g., frailty, and cognitive and functional status
impairments) be considered dimensions of comorbidities?
Does a comprehensive index of clinical states and symptoms
serve as a better indicator of outcomes than disease states?
What are the valid approaches to advancing knowledge of
comorbidities; and what should be the starting point or
anchor for these developments (e.g., types of diseases, types
of outcomes, or type of populations to be studied, such as age
groups)?
Thus, the concept of comorbidities and its measurement
is in need of meaningful debate by the scientific and clinical
communities. In the meantime, comorbidities should be
contextualized as an emerging science rather than biological
realities or “scientific givens” [20]. It is important to be
aware of the real risks of overtreatment and overemphasis
of medical interventions while underutilization of social
and behavioral interventions towards prevention and disease
management [20]. Researchers, clinicians, and policy makers
are urged to draw careful conclusions and implications in
interpreting comorbidity research findings.
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